

Fax completed form to: (855) 840-1678
If this is an URGENT request, please call (800) 882-4462 (800.88.CIGNA)

## Khapzory (levoleucovorin)

PHYSICIAN INFORMATION			PATIENT INFORMATION				
* Physician Name:  Specialty:	·		*Due to privacy regulations we will not be able to respond via fax with the outcome of our review unless all asterisked (*) items on this form are completed *				
Office Contact Person:	,		form are completed.*  * Patient Name:				
Office Phone:			* Cigna ID: * Date of Birth:				
					Date of Diffit.		
Office Fax:			* Patient Street Address				
Office Street Address:			City:	State	:	Zip:	
City: Stat	e:	Zip:	Patient Phone:				
Urgency:  ☐ Standard  ☐ Urgent (In checking this box, I attest to the fact that applying the standard review time frame may seriously jeopardize the customer's life, health, or ability to regain maximum function)							
Medication requested: ☐ Khapzory 175mg powder for injection ☐ Khapzory 300mg powder for injection ☐ ICD10:							
Dose:	py: Duration of therapy:						
Is the requested medication for a chronic or long-term condition for which the prescription medication may be necessary for the life of the patient?							
Where will this medication be obtained?  Accredo Specialty Pharmacy (Cigna's nationally preferred specialty pharmacy)  Physician's office stock  Home Health / Home Infusion vendor (name):  CPT Code(s):  Facility and/or doctor dispensing and administering medication:  Facility Name:  Address (City, State, Zip Code):  State:  Tax ID#:							
Is the patient a candidate for home infusion? Does the physician have an in-office infusion site?					Yes [	= =	
Diagnosis related to use:  acute lymphocytic leukemia ( Adult T-cell leukemia/lymphom AIDS-related B-cell lymphome anal carcinoma bladder cancer Burkitt lymphoma central nervous system cance cervical cancer chronic lymphocytic leukemia colorectal cancer (CRC) diffuse large B-cell lymphome esophageal and esophagoga extranodal NK/T-cell lymphome follicular lymphoma (FL) gastric cancer hepatocellular carcinoma (HC) hepatosplenic gamma-delta high-grade B-cell lymphoma mantle cell lymphoma (MCL)	ma (ATLL) ers including a (CLL)/sma a (DLBCL) estric junction ma (nasal ty	g primary CNS lymph all lymphocytic lymph on cancers ype)	noma, brain metastase	s, leptomening	eal metastate	es	

<ul> <li>□ occult primary</li> <li>□ ovarian cancer/fallopian tube cancer/primary peritoneal cancer - mucinous carcinoma</li> <li>□ pancreatic adenocarcinoma</li> <li>□ peripheral T-cell lymphoma</li> <li>□ small bowel adenocarcinoma</li> <li>□ soft tissue sarcoma - rhabdomyosarcoma</li> <li>□ none of the above</li> </ul>						
(if none of the above) Which of the following best describes how the patient is or will be using Khapzory?  ☐ to diminish the toxicity and counteract the effects of impaired methotrexate elimination ☐ to diminish toxicity and counteract the effects of inadvertant overdosage of folic acid antagonists ☐ as rescue therapy after high-dose methotrexate therapy in osteosarcoma patient ☐ none of the above (if none of the above) What is the diagnosis related to use?						
Clinical Information:						
(if CRC) Does your patient have metastatic disease?	☐ Yes ☐ No					
(if CRC) Is/Will Khapzory be(ing) used in combination with fluorouracil (Adrucil, 5-FU)?	☐ Yes ☐ No					
(if CRC) Is Khapzory being given as part of adjuvant therapy?	☐ Yes ☐ No					
(if NOT CRC, if NOT none of the above) Is/Will Khapzory be(ing) used in combination with high-dose methotrexate (I	MTX)? ☐ Yes ☐ No					
Has the patient already been started on therapy with Khapzory?	☐ Yes ☐ No					
(if yes) Has the patient tried generic levoleucovorin calcium injection?	☐ Yes ☐ No					
(if no) Has the patient tried one generic levoleucovorin calcium injection or generic leucovorin injection?	☐ Yes ☐ No					
Additional Pertinent Information: (including disease stage, prior therapy, performance status, and names/dose of any agents to be used concurrently):	es/admin schedule					
Attestation: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan or insurer its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.						
Prescriber Signature: Date:						
Save Time! Submit Online at: <a href="https://www.covermymeds.com/main/prior-authorization-forms/cigna/">www.covermymeds.com/main/prior-authorization-forms/cigna/</a> or via SureScripts in your EHR.						

Our standard response time for prescription drug coverage requests is 5 business days. If your request is urgent, it is important that you call us to expedite the request. View our Prescription Drug List and Coverage Policies online at cigna.com.

V041525

"Cigna" is a registered service mark, and the "Tree of Life" logo is a service mark, of Cigna Intellectual Property, Inc., licensed for use by Cigna Corporation and its operating subsidiaries. All products and services are provided by or through such operating subsidiaries and not by Cigna Corporation. Such operating subsidiaries include, for example, Cigna Health and Life Insurance Company and Cigna Health Management, Inc. Address: Cigna Pharmacy Services, PO Box 42005, Phoenix AZ 85080-2005